EAErsan Atahan

Ersan Atahan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ersan Atahan has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of home-based telerehabilitation pranayama on sleep quality and wellbeing in mild to moderate obstructive sleep apnea syndrome. A randomized controlled trial

    by Zeynep Kaçar Akkoç, Rengin Demir, Rüstem Mustafaoğlu, Ömer Önder Önder, Baha Naci, Ersan Atahan

    Obstructive sleep apnea syndrome (OSAS) is a common disorder that causes repeated airway obstruction, disrupted breathing, and fragmented sleep. This study aimed to investigate the effects of Pranayama on sleep quality, daytime sleepiness, quality of life, fatigue, depression, and anxiety in patients with OSAS. This study was designed as an open-label, prospective, randomized controlled trial. OSAS patients meeting the inclusion criteria were randomly assigned to either an Intervention group or a Control group. Pranayama training was applied to the Intervention group for 8 weeks, 7 days a week, and 3 times a day for 15 min. In addition, a single 15-minute session, 3 days a week, was conducted online under the supervision of a physiotherapist. The control group did not receive any intervention. Primary outcome was sleep quality (Pittsburgh Sleep Quality Index, PSQI). Secondary outcomes included daytime sleepiness (Epworth Sleepiness Scale, ESS), Fatigue Severity Scale (FSS), Functional Outcomes of Sleep Questionnaire (FOSQ), Nottingham Health Profile (NHP), and Hospital Anxiety and Depression Scale (HADS). All outcome measures were assessed at baseline and reassessed after the 8-week intervention period. Thirty-eight OSAS patients meeting the inclusion criteria were randomly assigned to either an Intervention group (n = 19) or a Control group (n = 19). Four participants (two in each group) were lost to follow-up, leaving the data of 34 participants (17 per group) available for inclusion in the final analysis. In the intervention group, PSQI scores decreased from 9.12 ± 4.71 to 6.88 ± 4.45 (p < 0.001), whereas no improvement was observed in the control group. Regarding the primary outcome, the reduction in PSQI scores was significantly greater in the intervention group than in the control group (p < 0.001). The ESS scores also decreased significantly in the intervention group, from 9.41 ± 6.15 to 7.41 ± 6.18 (p = 0.006, with a significant between-group difference (p < 0.001). Fatigue severity decreased in the intervention group (FSS change: 0.53 ± 0.70; p = 0.006), with a significant between-group difference (p = 0.037). The FOSQ score improved markedly, with significant gains in FOSQ total score (− 0.38 ± 0.25 vs. 0.14 ± 0.22 in controls; p < 0.001) and in activity level and vigilance subdomains (both p < 0.001). The HADS-anxiety scores decreased by 1.94 ± 3.94 (p = 0.059) and depression scores by 3.06 ± 2.05 (p < 0.001) in the intervention group, with significant between-group differences for both anxiety (p = 0.008) and depression (p < 0.001). Pranayama was an effective adjunct therapy for these OSAS patients, and incorporating it into treatment strategies may enhance patient outcomes. NCT04632147/22.10.2020.

  • Open Access

    Characteristics of small airway disease in patients with HIV infection: insights from spirometry and impulse oscillometry

    by Ilgim Vardaloglu, Buket Caliskaner Ozturk, Hazal Cansu Culpan, Bilgul Mete, Fehmi Tabak, Ersan Atahan

    Background: Airway diseases that are independent of smoking behaviour are frequent in people living with HIV (PLWH). Spirometry, the gold standard for diagnosing airway diseases, may not detect small airway disease (SAD) when forced expiratory volume in 1 s/forced vital capacity is normal. However, impulse oscillometry (IOS) can detect SAD even when the spirometry is normal. This study aims to evaluate characteristics of SAD in PLWH by using IOS and exploring the diagnostic performance of IOS measurements to detect SAD. Methods: This cross-sectional study included 127 PLWH on antiretroviral therapy without known airway disease. IOS was done first, followed by spirometry. Patients whose maximal mid-expiratory flow (MMEF) value was below 65% were defined as having spirometric SAD. Clinical characteristics and IOS measures were compared between those who had and those who did not have SAD. A receiver operating characteristic analysis was done to determine the diagnostic performance of IOS measures to diagnose spirometric SAD. Results: Mean age was 43.5±12.5 years and 60 patients were non-smokers. Spirometric SAD was observed in 34% of all patients. R5, R5–R20, AX and Fres were significantly higher in the patients who had spirometric SAD. Smoking history, duration of antiretroviral therapy and history of pneumonia were significantly associated with SAD. The optimal cut-off value for R5–R20 was 0.08 for SAD (sensitivity of 71.8% and specificity of 58.1%) and the optimal cut-off value for AX was 0.55 (sensitivity of 51.2% specificity of 91.7%). Conclusion: SAD is common in PLWH and IOS may serve as a supportive tool for the clinical assessment of small airway involvement.

  • Open Access

    Prediction of Histological Subtype Based on Segmental Localization of Malignant Pulmonary Nodule in the Upper Lobe of the Lung

    by Aysegul Gencer, Ersan Atahan, Bilun Gemicioglu, Sermin Borekci, Buket Caliskaner Ozturk

    Background: Studies have shown that malignant pulmonary nodules frequently occur in the upper lobes of the lung. However, there is no data on their distribution according to segments. The aim of this study is to predict the histological subtype of lung cancer based on the segment localization of malignant pulmonary nodules located in the upper lobe of the lung. Methods: Between March 1, 2018, and November 1, 2024, 2402 patients who applied to the pulmonary diseases outpatient clinic and were scheduled for further investigation after thoracic CT scans revealed pulmonary nodules measuring 8 mm or larger were screened. The demographic characteristics, pulmonary nodule size, and histological subtypes of 154 patients diagnosed with non‐small cell lung cancer (NSCLC) in further investigations were compared according to the upper lobe segments of the lung: apicoposterior and anterior. Results: Adenocarcinoma percentage was significantly higher in the apicoposterior group, while squamous cell carcinoma percentage was significantly higher in the anterior group ( p = 0.010). Conclusions: NSCLC localized in the apicoposterior segment of the upper lobes of the lung tends to be adenocarcinoma, while those localized in the anterior segment tend to be squamous cell carcinoma. Tumor size less than 3 cm with apicoposterior localization is independently associated with the adenocarcinoma histological subtype.

  • Miliary Tuberculosis Accompanied by Hemophagocytic Syndrome: A Rare Case

    by Aytan Ismayılova, Nigar Aliyeva, Ersan Atahan

    Giriş: Miliyer tüberküloz (TB), erken dönemde klinik ve radyolojik olarak nonspesifik seyredebildiği için tanıda gecikmelere yol açabilmektedir. Hemofagositik lenfohistiyositoz (HLH) eşlik ettiğinde klinik tablo hızla kötüleşebilir ve mortalite artar. Olgu Sunumu: Altmış yedi yaşındaki erkek hasta, bir aydır süren ateş, halsizlik, nefes darlığı ve ishal şikayetleriyle başvurdu. İlk kültürler ve görüntülemeler tanısal değildi. Üçüncü haftada gelişen pansitopeni, hipertrigliseridemi, hipofibrinojenemi ve periferik yaymada hemofagositik hücreler sekonder HLH’yi düşündürdü. Kemik iliği aspiratında ARB pozitifliği ve nekrotizan granülom saptandı. Takipte YRBT ve PET-CT’de tipik miliyer dağılım izlendi. Antitüberküloz tedavi sonrası üç günde ateş yanıtı alındı. Sonuç: Bu olgu, açıklanamayan ateş ve sitopeni ile başvuran hastalarda miliyer TB ve TB-HLH’nin mutlaka akılda tutulması gerektiğini vurgulamaktadır. Kemik iliği biyopsisi, hem dissemine TB hem de HLH tanısında kritik öneme sahiptir. Erken tanı ve tedavi prognozu belirgin şekilde iyileştirebilir.

  • Evaluation of obstructive sleep apnea syndrome in sarcoidosis patients: a clinical and polysomnographic analysis

    by Nigar Aliyeva, Aytan İsMayilova, Buket Çalişkaner Öztürk, Günay Can, Ersan Atahan

    Background While some studies suggest an elevated risk of obstructive sleep apnea (OSA) in sarcoidosis, comprehensive research remains limited. This study aims to assess the prevalence of OSA among sarcoidosis patients, compare its occurrence with the general population, and evaluate the clinical and polysomnographic features of sarcoidosis patients diagnosed with OSA. Methods This prospective observational study identified 150 out of 290 sarcoidosis-diagnosed patients with OSA symptoms. Of these, 52 underwent polysomnography (PSG), and 45 patients with an Apnea-Hypopnea Index (AHI) ≥ 5 events/hour were included. The control group consisted of 48 OSA patients without lung disease history who had previously undergone PSG. Demographic, anthropometric, clinical, and polysomnographic parameters were compared between groups. Respiratory function test results and pulmonary involvement were also analyzed for sarcoidosis patients. Results Ninety-three patients (45 sarcoidosis, 48 controls) were included. Sarcoidosis patients had a mean age of 50.7 ± 9.5 years, with 68.8% female and 55.5% obese. Pulmonary involvement was observed in 20%, and 62.5% of actively treated patients received corticosteroids. The median AHI and ODI values for sarcoidosis patients were 17.9 and 13.5, respectively. Supine apnea count was significantly higher in sarcoidosis patients (p = 0.003). N3 sleep stage proportion was significantly lower in severe OSA (p = 0.006). Pulmonary involvement increased with OSA severity: 2.2% in mild, 6.6% in moderate, and 11.1% in severe cases. Conclusion OSA is a common comorbidity in sarcoidosis; warranting further investigation to optimize management in this population.

  • Open Access

    Comorbidity Burden in Chronic Thromboembolic Pulmonary Hypertension: Implications and Outcome

    by Burcak Kilickiran Avci, Ibrahim Basarici, Mehmet Akbulut, Halil Atas, Yalin Tolga Yaylali, Umit Yasar Sinan, Ersan Atahan, Murat Meric, Baris Kaya, Kardelen Ohtaroglu Tokdil, et al.

    Background and Objectives: Comorbidities, the coexistence of additional conditions with a primary disease, are increasingly prevalent, complicating disease management and clinical outcomes. While CTEPH is a well-studied condition in terms of risk factors and outcomes, the specific impact of comorbidity burden on clinical presentation, treatment decisions, and survival remains insufficiently explored. This study aims to assess the prevalence and burden of comorbidities in CTEPH and to examine their associations with initial clinical characteristics, treatment allocation, and survival, stratified by pulmonary endarterectomy (PEA) status. Materials and Methods: We included 187 CTEPH patients from eight tertiary PH centers (2009–2020). Cardiovascular and non-cardiovascular comorbidities were identified and categorized as 0, 1–2, or ≥3. Their impact on baseline six-minute walk distance (6MWD), hemodynamic parameters, operability decision, and survival was assessed. Results: Comorbidities were prevalent (90%), with 49% of patients having three or more. Hypertension, diabetes, coronary artery disease, and chronic kidney disease (CKD) were associated with lower 6MWD. Hypertension, atrial fibrillation, left heart failure, and CKD were linked to elevated right atrial and pulmonary arterial wedge pressures. Comorbidities rendered 39% of anatomically operable patients ineligible for surgery. No single comorbidity predicted survival. Among PEA patients, those with ≥3 cardiovascular comorbidities had worse survival (p = 0.010). In contrast, the comorbidity burden did not impact survival in non-PEA patients. PEA surgery (HR 0.342, 95% CI 0.130–0.899, p = 0.030) and baseline 6MWD (HR 0.997, 95% CI 0.994–1.000, p = 0.036) were identified as independent predictors of mortality. Conclusions: A high comorbidity burden is common in CTEPH and influences functional status, hemodynamics, and operability decisions. It may worsen long-term outcomes after PEA but appears to be less prognostic in non-operated patients, where disease severity seems to be the primary determinant of outcomes. These findings underscore the importance of careful operability assessment and proactive comorbidity management.


  • Open Access

    Thoracic CT Screening in a Population With Unidentified Lung Cancer Risk Factors: Does It Facilitate the Early Diagnosis of Lung Cancer?

    by Aysegul Gencer, Buket Caliskaner Ozturk, Gizem Senkardesler, Ersan Atahan, Bilun Gemicioglu, Sermin Borekci

    Background: Lung cancer is the predominant cause of cancer‐related mortality globally. Computed tomography (CT) scanning is employed to enhance the early diagnosis of lung cancer by screening for risk factors. This study aimed to examine the impact of CT scanning on the incidence of lung cancer detection in a group with unidentified risk factors for the disease. Methods: Data from two patient cohorts were analyzed: the “study group,” comprising individuals with a CT‐detected pulmonary nodule of ≥ 8 mm and unknown lung cancer risk factors, and the “control group,” consisting of individuals with a pulmonary nodule of ≥ 8 mm identified by CT scan due to known lung cancer risk factors. Results: No significant difference was seen between the groups regarding malignancy frequency ( p = 0.155) and early‐stage occurrence ( p = 0.842). Conclusions: The incidence of lung cancer in pulmonary nodules measuring ≥ 8 mm is not influenced by the presence of lung cancer risk factors.

  • Open Access

    Treatment and long term follow-up results in patients with pulmonary vascular thrombosis related to COVID-19

    by Nigar Aliyeva, Buket Çalişkaner Öztürk, Burçak Kiliçkiran Avci, Ersan Atahan

    Pulmonary embolism is a complication of COVID-19 infection. The aim of this study is to assess prognosis and treatment response, including incidences of chronicity, relapse, and mortality among outpatients diagnosed with COVID-19-related pulmonary embolism between 2020 and 2022. A total of 101 patients with pulmonary embolism, started on anticoagulation during or within a month of COVID-19 infection, were included after testing positive by PCR. Data about comorbidities, Pulmonary Embolism Severity Index scores, PE diagnostic modalities, biochemical parameters, and transthoracic echocardiographic findings at diagnosis and at 24-month follow-up were collected. Cardiac catheterization parameters were recorded and compared between groups at diagnosis and at the 24-month follow-up. Groups were comparable with respect to gender, age, body mass index, and comorbidity score. Use of Q-SPECT for diagnosis was found significantly higher in patients with COVID-19-related pulmonary embolism (P < .001). The incidence of deep vein thrombosis was similar. In the study group, 43.6% of patients received anticoagulants for 3 months, with 49.1% using low molecular weight heparin and 50.9% using direct oral anticoagulants. At 24 months, rate of patients continuing treatment was comparable between groups. Specific pulmonary artery blockage value was found to be higher in patients with chronic thromboembolic pulmonary hypertension compared to those who demonstrated a response to pulmonary embolism treatment (P = .009). No adverse effects of anticoagulant therapy were observed during course of treatment. Over 24-month follow-up period, mortality, relapse, chronic thromboembolic hypertension and thromboembolic disease was observed in 2%, 2.2%, 4.9%, and 9.9% of patients, respectively.


  • Open Access

    Small airway resistance in obese and nonobese patients with obstructive sleep apnea syndrome using impulse oscillometry

    by Nejdiye Güngördü, Aytan İsMayi̇lOva, Nigar Ali̇yEva, Tamer A M Alhelou, Ayşenur ÖZDİL ESER, Ilgım VARDALOĞLU KOYUNCU, Nihal Enşen, Ersan Atahan, Şermin Börekçi̇, Bilun Gemi̇cİoĞlu

    Background/aim: There is limited information on the pathologic changes in the small airways among obese and nonobese patients with obstructive sleep apnea syndrome (OSAS). Impulse oscillometry (IOS) measures airway resistance and reactance independently of patient effort. This study aimed to compare airway resistance in small airways using IOS between obese and nonobese patients with OSAS.Materials and methods: In this real-life cross-sectional study, demographic information was collected from obese and nonobese subjects diagnosed with moderate and severe OSAS without any other underlying diseases. Spirometry and IOS measurements were conducted, and the values of both groups were statistically analyzed.Results: The nonobese group had a mean age of 45.6 ± 11.7 years (median 45), while the obese group had a mean age of 48.4 ± 9.5 years (median 47.5). The mean body mass index (BMI) for the nonobese group was 26.2 ± 2.1 kg/m2 (median 27 kg/m2), and for the obese group, it was 35.6 ± 6.4 kg/m2 (median 33 kg/m2). Statistically significant differences were observed between the two groups in R5 - R20 percentage, reactance area (AX), and resonant frequency (Fres) values (p < 0.05).Conclusion: Among obese OSAS patients, there is an increase in resistance in small airways as indicated by IOS values. IOS shows promise as a potential screening tool for diagnosing OSAS.